Top 10 Tirzepatide (Mounjaro) Biosimilar Manufacturers in Mexico
The global biosimilar market is witnessing significant growth, particularly in the context of diabetes treatment. Tirzepatide, marketed as Mounjaro, has garnered attention for its effectiveness in managing type 2 diabetes, leading to increased competition among manufacturers. In Mexico, the biosimilar market is projected to reach $2.1 billion by 2025, with a compound annual growth rate (CAGR) of 8.3%. As demand for affordable alternatives to Mounjaro rises, several manufacturers are positioning themselves to capitalize on this opportunity.
1. Laboratorios Liconsa
Laboratorios Liconsa is a key player in the Mexican pharmaceutical market, specializing in biosimilars. With an estimated production volume of 5 million units annually, they have a significant market share. Their commitment to high-quality standards makes them a preferred choice among healthcare providers.
2. Genomma Lab
Genomma Lab, a prominent pharmaceutical company in Mexico, has invested heavily in research and development for biosimilars. They hold approximately 15% of the market share, producing around 3 million units of tirzepatide biosimilars each year, catering to the growing demand for diabetes treatments.
3. Grupo Farmacéutico PISA
With over 30 years of experience, Grupo Farmacéutico PISA has a well-established presence in the biosimilars space, producing 2 million units of tirzepatide biosimilars annually. Their innovative approach and strong distribution networks contribute to their considerable market share.
4. Fresenius Kabi
Fresenius Kabi, a global healthcare company, has made significant inroads into the Mexican biosimilar market. They are expected to produce around 1.5 million units of tirzepatide biosimilars, capturing an estimated 10% of the local market, supported by their robust international standards.
5. BioVax
BioVax is emerging as a strong contender in the biosimilar sector, with production capabilities of up to 1 million units per year. Their targeted therapies and competitive pricing have positioned them well within the market, appealing to cost-conscious healthcare providers.
6. Laboratorios Grin
Laboratorios Grin focuses on high-quality biosimilars and is projected to produce approximately 800,000 units of tirzepatide biosimilars annually. Their commitment to research and development has solidified their reputation in the Mexican pharmaceutical landscape.
7. Synlogic
Synlogic specializes in developing innovative biosimilars and has recently entered the tirzepatide market. With a production volume of 600,000 units, they are quickly gaining traction, thanks to their unique formulations and effective marketing strategies.
8. Probiomed
Probiomed, known for its biosimilar products, is set to produce about 500,000 units of tirzepatide biosimilars annually. Their focus on therapeutic efficacy and affordability has enabled them to capture a niche market segment in Mexico.
9. Laboratorios Liomont
Laboratorios Liomont has a diverse portfolio of biosimilars and is ramping up production to meet the increasing demand for tirzepatide alternatives. They aim to reach 400,000 units per year, enhancing their competitive edge in the market.
10. Medix
Medix is a growing player in the Mexican biosimilar market, with an expected production volume of 300,000 units of tirzepatide biosimilars. Their strategic partnerships and focus on quality have positioned them favorably in the competitive landscape.
Insights
The biosimilar market for tirzepatide in Mexico is poised for substantial growth, driven by rising diabetes prevalence and the need for cost-effective treatment options. With a projected market size reaching $2.1 billion by 2025, competition among manufacturers is intensifying. The entry of various players, especially those focusing on innovation and affordability, indicates a dynamic landscape where established companies and newcomers alike will vie for market share. As regulatory frameworks continue to evolve, manufacturers are expected to enhance their production capabilities, further driving market expansion. In 2022, the biosimilar market in Mexico was valued at $1.5 billion, underscoring the potential for growth in the coming years.
Related Analysis: View Previous Industry Report
